Cash and cash equivalents are anticipated to be sufficient to fund operations as currently planned into 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- YMAB Upcoming Earnings Report: What to Expect?
- Y-mAbs Therapeutics announces naxitamab-gqgk recommended by NCCN
- Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
- Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform
- Y-mAbs Therapeutics downgraded to Underperform from Neutral at BofA